Give us a call 215-275-1556

 Compliance Blog

A Cloudy Future for the Sunshine Act

The due date for posting another year's worth of Physician Payment  Sunshine Act (a.k.a. Open Payments) data is fast approaching.  But the future for the Sunshine Act is cloudy.  A new Republican...

read more

Is Drug Price Transparency DOA?

Once again drug price transparency is in the news. Now it appears that efforts to improve pricing visibility are dead on arrival.  If we look at recent actions by Pfizer and Mylan, it may well be....

read more

Drug Pricing Need Not Be This Hard

Mylan's EpiPen continues making news, prompting patients to compare drug prices. They look at the prices in Canada, our closest neighbor, and they wonder why the prices here are two to three times...

read more

Mylan’s Ethical Meltdown

It has been quite a month for Mylan beginning with its first ethical lapse when it raised the price of the EpiPen by $500 from its 2008 price.  Facing a tidal wave of criticism, Mylan, a week later,...

read more

Pharma Pricing & One Bold CEO

It did not take long.  In the midst of the pricing debacle created by Mylan and the EpiPen, one bold CEO has stepped forward.   Brent Saunders, Allergan's leader, has taken a clear stand.  Writing...

read more

Pricing – The Next Alamo

It started with Turing, continued with Valeant. moved on to Gilead and now has engulfed Mylan.  What is it?  It is pharmaceutical pricing.  The questions are simple. How can pharmaceutical companies...

read more

Transparency’s Uncertain Future

I just returned from speaking at CBI's 10th Annual Forum on Transparency and Aggregate Spend.  After 10 years and 3 CMS Open Payments reporting cycles, I'm struck by how uncertain the once bright...

read more

CVS, Opioids & Lack of Compliance

The Year of the Pharmacy continues as CVS again makes negative headlines involving opioids.  This time, a pharmacist in Georgia is accused of stealing more than 3,000 pills from them including...

read more